Published in:

17-07-2024 | Radiotherapy | Research

Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations

Authors: D. Pezzulla, G. Chiloiro, E. M. Lima, G. Macchia, C. Romano, S. Reina, G. Panza, S. Cilla, A. G. Morganti, F. Cellini, M. A. Gambacorta, F. Deodato

Published in: Clinical & Experimental Metastasis | Issue 5/2024

Abstract

A large pooled analysis of liver oligometastases, classified accordingly to the ESTRO/EORTC recommendations, treated by stereotactic radiotherapy (SBRT) and Radiosurgery (SRS) was carried out. The clinical and dosimetric data of patients who underwent SBRT/SRS for liver metastases were analysed in terms of efficacy and toxicity profile. In particular, the Local Control (LC), the Distant Metastases Free Survival (DMFS), the Disease-Free Survival (DFS), the Overall Survival (OS), and the Next Systemic Therapy Free Survival (NEST-FS) rates were analysed. 113 patients (M/F: 49/64), accounting for a total of 150 hepatic lesions (March 2006–February 2023) in two Italian radiotherapy Institutions were evaluated. Median age was 67 years old (36–92) and 48 (42.5%) patients had at least one comorbidity. The majority of the lesions were induced (30.7%) or repeated oligoprogressive (12.7%) metastases. 98 lesions were treated with more than one daily fraction (mainly 50 Gy in 5 fractions), while 52 were radiosurgery treatments (mainly 32 Gy). The treatment response at 3–4 months was evaluable in 147 lesions: complete response was 32.0%, partial response 17.0%, and stable disease 32.0%. Actuarial LC, DMFS, DFS, OS, and NEST-FS at 1 year were 75.8%, 37.7%, 34.9%, 78.7%, and 59.4% respectively; while actuarial LC, DMFS, DFS, OS, and NEST-FS at 2 years were 52.1%, 24.9%, 21.9%, 51.3%, and 36.8%, respectively. The achievement of complete response, synchronous oligometastases, and no treatment interruptions correlated with a more favorable outcomes. As per the toxicity profile, we registered only two acute and one late toxicity cases higher than grade 2. Stereotactic treatment for liver metastases seems to be a safe and promising option in terms of local control. The best results in term of outcomes have been obtained in patients with complete response, synchronous oligometastases, favorable histology, and no treatment interruptions.

Available only for authorised users

de la Peña C, Gonzalez MF, González C, Salazar JM, Cruz B (2020) Stereotactic body radiation therapy for liver metastases: clinical outcomes and literature review. Rep Pract Oncol Radiother 25(4):637–642. https://doi.org/10.1016/j.rpor.2020.04.021CrossRefPubMedPubMedCentral

Wulf J, Hadinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in thelung and liver. Strahlenther Oncol 177(12):645–655CrossRef

Wulf J, Guckenberger M, Haedinger U et al (2006) Stereotactic radiotherapy of pri-mary liver cancer and hepatic metastases. Acta Oncol 45:838–847CrossRefPubMed

Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hep-atic metastases. Int J Radiat Oncol Biol Phys 67(3):793–798CrossRefPubMed

Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, Kroeze SGC, Mayinger M, Guckenberger M, Andratschke N (2022) Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol 168:256–264. https://doi.org/10.1016/j.radonc.2022.01.019CrossRefPubMed

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10CrossRefPubMed

Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R et al (2014) The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol 11:549–557CrossRefPubMed

Choti MA, Sitzman JV, Tiburi MF et al (2002) Trends in long-term survivalfollowing liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766CrossRefPubMedPubMedCentral

Tomlinson JS, Jarnagin WR, DeMatteo RP, Fog Y et al (2007) Actual 10-year sur-vival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580CrossRefPubMed

10.

Small R, Lubezky N, Ben-Haim M (2007) Current controversies in the surgicalmanagement of colorectal cancer metastases to the liver. Isr Med Assoc J 9(10):742–747PubMed

11.

Garrean S, Hering J, Saied A, Helton WS, Espat NJ (2008) Radiofrequency ablation ofprimary and metastatic liver tumors: a critical review of the literature. Am J Surg 195(4):508–520CrossRefPubMed

12.

Solbaiti L, Livraghi T, Golberg SN et al (2001) Percutaneous radiofrequency ablation ofhepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166CrossRef

13.

Groeschl RT, Pilgrim CH, Hanna EM et al (2014) Microwave ablation for hepatic malig-nancies: a multinstitutional analysis. Ann Surg 259(6):1195–1200CrossRefPubMed

14.

Volg TJ, Zangos S, Eichler K, Yakaoub D, Nabil M (2007) Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hep-atic chemoperfusion: an update. Eur Radiol 17(4):1025–1034CrossRef

15.

Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86(2):336–342. https://doi.org/10.1016/j.ijrobp.2012.12.021CrossRefPubMed

16.

Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiationinduced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821CrossRefPubMed

17.

Timmerman RD, Kavanagh BD, Cho LC et al (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952CrossRefPubMed

18.

Lee J, Shin IS, Yoon WS, Koom WS, Rim CH (2020) Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol 145:63–70. https://doi.org/10.1016/j.radonc.2019.12.004CrossRefPubMed

19.

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1CrossRefPubMed

20.

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRefPubMed

21.

National Cancer Institute Common Terminology Criteria for Adverse Events v.4.03 (CTCAEv.4.03)

22.

Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081CrossRefPubMedPubMedCentral

23.

Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, Conibear J, Dunne EM, Eaton DJ, Franks KN, Good JS, Harrow S, Hatfield P, Hawkins MA, Jain S, McDonald F, Patel R, Rackley T, Sanghera P, Tree A, Murray L (2022) UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol (R Coll Radiol) 34(5):288–300. https://doi.org/10.1016/j.clon.2022.02.010CrossRefPubMed

24.

van der Pool AE, Méndez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97(3):377–382. https://doi.org/10.1002/bjs.6895CrossRefPubMed

25.

Méndez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i–ii study. Acta Oncol 45(7):831–837. https://doi.org/10.1080/02841860600897934CrossRefPubMed

26.

Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578. https://doi.org/10.1200/JCO.2008.19.6329CrossRefPubMed

27.

Jackson WC, Tao Y, Mendiratta-Lala M et al (2018) Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys 100(4):950–958. https://doi.org/10.1016/j.ijrobp.2017.12.014CrossRefPubMed

28.

Petrelli F, Comito T, Barni S et al (2018) Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol 129(3):427–434. https://doi.org/10.1016/j.radonc.2018.06.035CrossRefPubMed

29.

Lanciano R, Lamond J, Yang J et al (2012) Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol 2:23. https://doi.org/10.3389/fonc.2012.00023CrossRefPubMedPubMedCentral

30.

Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591. https://doi.org/10.1200/JCO.2008.20.0600CrossRefPubMed

31.

Rule W, Timmerman R, Tong L et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18(4):1081–1087. https://doi.org/10.1245/s10434-010-1405-5CrossRefPubMed

32.

Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A (2010) Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients. Eur J Cancer 46(6):1026–1032. https://doi.org/10.1016/j.ejca.2010.01.008CrossRefPubMed

33.

Uder L, Nachbar M, Butzer S, Boldt J, Baumeister S, Bitzer M, Königsrainer A, Seufferlein T, Hoffmann R, Gatidis S, Nikolaou K, Zips D, Thorwarth D, Gani C, Boeke S (2023) Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases. Front Oncol 12:1095633. https://doi.org/10.3389/fonc.2022.1095633CrossRefPubMedPubMedCentral

34.

Ugurluer G, Mustafayev TZ, Gungor G et al (2021) Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience. Radiat Oncol J 39(1):33–40. https://doi.org/10.3857/roj.2020.00976CrossRefPubMedPubMedCentral

35.

Yu J, Kim DH, Lee J et al (2022) Radiofrequency ablation versus stereotactic body radiation therapy in the treatment of colorectal cancer liver metastases. Cancer Res Treat 54(3):850–859. https://doi.org/10.4143/crt.2021.674CrossRefPubMed

36.

Macchia G, Lazzari R, Colombo N et al (2020) A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist 25(2):e311–e320CrossRefPubMed

37.

Macchia G, Nardangeli A, Laliscia C et al (2022) Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Int J Gynecol Cancer 32(6):732–739CrossRefPubMed

38.

Macchia G, Pezzulla D, Campitelli M et al (2023) Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer (MITO-RT2/RAD study): a large, real-world study in collaboration with AIRO GYN, MITO and MANGO groups. Int J Radiat Oncol Biol Phys 32(7):1

39.

Cilla S, Campitelli M, Antonietta Gambacorta M, Michela Rinaldi R, Deodato F, Pezzulla D, Romano C, Fodor A, Laliscia C, Trippa F, De Sanctis V, Ippolito E, Ferioli M, Titone F, Russo D, Balcet V, Vicenzi L, Di Cataldo V, Raguso A, Giuseppe Morganti A, Ferrandina G, Macchia G (2023) Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: a multi-institutional study. Radiother Oncol 191:110072. https://doi.org/10.1016/j.radonc.2023.110072CrossRefPubMed

40.

Klement RJ, Abbasi-Senger N, Adebahr S et al (2019) The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer 19(1):173. https://doi.org/10.1186/s12885-019-5362-5CrossRefPubMedPubMedCentral

41.

Reynders K, Illidge T, Siva S et al (2015) The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41:503–510CrossRefPubMedPubMedCentral

42.

Joo JH, Park J-H, Kim JC, Chang Sik Y, Lim S-B, Park IJ, Kim TW, Hong YS, Kim K-P, Yoon SM, Park J, Kim JH (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99(4):876–883. https://doi.org/10.1016/j.ijrobp.2017.07.030CrossRefPubMed

43.

Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117(17):4060–4069. https://doi.org/10.1002/cncr.25997CrossRefPubMed

44.

Aitken K, Tree A, Thomas K et al (2015) Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases: can we change the therapeutic paradigm? Clin Oncol (R Coll Radiol) 27(7):411–419. https://doi.org/10.1016/j.clon.2015.03.006CrossRefPubMed

45.

Folkert MR, Meyer JJ, Aguilera TA et al (2021) Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys 109(5):1387–1395. https://doi.org/10.1016/j.ijrobp.2020.12.012CrossRefPubMed

46.

Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78(2):486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020CrossRefPubMed

47.

Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830. https://doi.org/10.1080/02841860600904854RusthovenCrossRefPubMed

48.

Nicosia L, Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Bonù M, Corradini S, Tolia M, Alongi F (2020) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146(9):2351–2358. https://doi.org/10.1007/s00432-020-03223-9CrossRefPubMed

49.

Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, Alexander AS, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, Olson RA (2022) Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys 114(5):849–855. https://doi.org/10.1016/j.ijrobp.2022.08.026CrossRefPubMed

Title: Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations
Authors: D. Pezzulla
G. Chiloiro
E. M. Lima
G. Macchia
C. Romano
S. Reina
G. Panza
S. Cilla
A. G. Morganti
F. Cellini
M. A. Gambacorta
F. Deodato
Publication date: 17-07-2024
Publisher: Springer Netherlands
Keywords: Radiotherapy
Metastasis
Published in: Clinical & Experimental Metastasis / Issue 5/2024
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-024-10301-6

Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer

Open Access
Cytostatic Therapy
Research

A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer

Colorectal Cancer
Research

Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma

Neuroblastoma
Research

Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis

Open Access
Metastasis
Review

Correction: Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma

Neuroblastoma
Correction

Stress-induced phosphoprotein 1: how does this co-chaperone influence the metastasis steps?

Metastasis
Review

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Genetic Testing
On-demand Webinar

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:

Illumina, Inc., and Eli Lilly and Company

Dr. Vivek Subbiah

Dr. Alexander Drilon

Dr. Michelle Williams

Developed by: Springer Healthcare

Watch now

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations

Abstract

Other articles of this Issue 5/2024

Microarray-based detection and expression analysis of drug resistance in an animal model of peritoneal metastasis from colon cancer

A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer

Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma

Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis

Correction: Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma

Stress-induced phosphoprotein 1: how does this co-chaperone influence the metastasis steps?

Women’s health knowledge hub

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content